Bio News

Denmark’s Genmab and U.S.-based AbbVie said a Phase 3 trial found that combining the bispecific antibody Epkinly with standard chemotherapy reduced the risk of disease progression or death by 51% compared with chemotherapy alone.
In the trial of 900 newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL), the Epkinly combination group recorded a relative risk reduction that exceeded investor expectations of about 40% and showed better results than Roche’s antibody-drug conjugate Polivy.
Genmab and AbbVie plan to discuss the results with regulators and present the data at a future medical meeting, while TD Cowen projected that Epkinly could generate $3 billion in annual sales.

Biobook Team
biobookmedia@biobook.co.krEuropean CHMP Recommends Approval of AstraZeneca’s Blood Pressure Drug Baxpendi
Novo Seeks U.S. and European Approval for Sickle Cell Drug Etavopivat
Rezolute Meets Primary Endpoint in Phase 3 Trial for Tumor Hyperinsulinism; FDA Meeting Ahead
Five Brain Disease Startups Raise $450 Million in a Few Weeks
American Cancer Society Revises Prostate Cancer Screening Guidelines for First Time in 16 Years
Shin Dong-kook Raises Stake in Hanmi Science to 30.18% With Over-the-Counter Purchase of 1.38 Million Shares